Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open‐Access ALS clinical trials database

Introduction: Urate has been identified as a predictor of amyotrophic lateral sclerosis (ALS) survival in some but not all studies. Here we leverage the recent expansion of the Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) database to study the association between urate levels and ALS survival. Methods: Pooled data of 1,736 ALS participants from the PRO‐ACT database were analyzed. Cox proportional hazards regression models were used to evaluate associations between urate levels at trial entry and survival. Results: After adjustment for potential confounders (i.e., creatinine and body mass index), there was an 11% reduction in risk of reaching a survival endpoint during the study with each 1‐mg/dL increase in uric acid levels (adjusted hazard ratio 0.89, 95% confidence interval 0.82–0.97, P < 0.01). Discussion: Our pooled analysis provides further support for urate as a prognostic factor for survival in ALS and confirms the utility of the PRO‐ACT database as a powerful resource for ALS epidemiological research. Muscle Nerve 57: 430–434, 2018

[1]  N. Shinomiya,et al.  Pathogenic GLUT9 Mutations Causing Renal Hypouricemia Type 2 (RHUC2) , 2011, Nucleosides, nucleotides & nucleic acids.

[2]  J. Kaye,et al.  Uric acid as a CNS antioxidant. , 2010, Journal of Alzheimer's disease : JAD.

[3]  M. Cudkowicz,et al.  Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[4]  V. Drory,et al.  Low uric acid levels in serum of patients with ALS: Further evidence for oxidative stress? , 2009, Journal of the Neurological Sciences.

[5]  M. Schwarzschild,et al.  Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release , 2015, Neurobiology of Disease.

[6]  O. Kano,et al.  GOUT AND RISK OF PARKINSON DISEASE: A PROSPECTIVE STUDY , 2008, Neurology.

[7]  Johann S. Hawe,et al.  Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression , 2014, Nature Biotechnology.

[8]  P. Bossuyt,et al.  Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. , 1995, Archives of neurology.

[9]  C. Tanner,et al.  Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.

[10]  J. Bernasovská,et al.  High frequency of SLC22A12 variants causing renal hypouricemia 1 in the Czech and Slovak Roma population; simple and rapid detection method by allele-specific polymerase chain reaction , 2015, Urolithiasis.

[11]  H. Hulkova,et al.  Novel allelic variants and evidence for a prevalent mutation in URAT1 causing renal hypouricemia: biochemical, genetics and functional analysis , 2013, European Journal of Human Genetics.

[12]  Ting-Ting Huang,et al.  Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action , 2012, Neuroscience Letters.

[13]  B. Diamond,et al.  Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. , 1998, Archives of neurology.

[14]  O. Combarros,et al.  Genetic variability related to serum uric acid concentration and risk of Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[15]  T. Hirayama,et al.  Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. , 2012, Internal medicine.

[16]  M. Watabe,et al.  Caffeine and uric acid mediate glutathione synthesis for neuroprotection , 2011, Neuroscience.

[17]  Wei Song,et al.  Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population , 2014, Metabolic Brain Disease.

[18]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[19]  H. Zetterberg,et al.  Urate as a marker of development and progression in Parkinson's disease. , 2011, Drugs of today.

[20]  S. Cuzzocrea,et al.  Uric acid protects against secondary damage after spinal cord injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Chiò,et al.  Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. , 2014, JAMA neurology.

[22]  S. Paganoni,et al.  Serum urate at trial entry and ALS progression in EMPOWER , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[23]  Xiqun Chen,et al.  Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. , 2010, Biomarkers in medicine.

[24]  V. Drory,et al.  Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis , 2014, Journal of Neurology.

[25]  B. Firestein,et al.  Astroglia‐mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity , 2007, Glia.

[26]  Chun-Feng Liu,et al.  Neuroprotection by urate on 6‐OHDA‐lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway , 2012, Journal of neurochemistry.

[27]  A. Ascherio,et al.  Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[28]  A. Pestronk,et al.  Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III , 2009, Annals of neurology.

[29]  S. Cipriani,et al.  Protection of dopaminergic cells by urate requires its accumulation in astrocytes , 2012, Journal of neurochemistry.

[30]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Friedman,et al.  Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. , 2014, JAMA neurology.

[32]  M. Hernán,et al.  Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study , 2015, Annals of the rheumatic diseases.

[33]  S. Paganoni,et al.  Uric acid levels predict survival in men with amyotrophic lateral sclerosis , 2012, Journal of Neurology.

[34]  A. Wuerz,et al.  High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study , 2005, Journal of Neural Transmission.

[35]  J. Bártl,et al.  Novel mutations in xanthine dehydrogenase/oxidase cause severe hypouricemia: biochemical and molecular genetic analysis in two Czech families with xanthinuria type I. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[36]  S. Cipriani,et al.  Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration , 2012, Proceedings of the National Academy of Sciences.

[37]  B. Stibůrková,et al.  Novel homozygous insertion in SLC2A9 gene caused renal hypouricemia. , 2011, Molecular genetics and metabolism.

[38]  Ki-Wook Oh,et al.  Prognostic Role of Serum Levels of Uric Acid in Amyotrophic Lateral Sclerosis , 2015, Journal of clinical neurology.

[39]  Guangbo Zhang,et al.  Nrf2 Signaling Contributes to the Neuroprotective Effects of Urate against 6-OHDA Toxicity , 2014, PloS one.

[40]  Hiroshi Mitsumoto,et al.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. , 2013, Free radical biology & medicine.

[41]  S. Paganoni,et al.  Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis , 2011, Muscle & nerve.

[42]  M. Weisskopf,et al.  Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[43]  C. Tanner,et al.  Mendelian randomization of serum urate and parkinson disease progression , 2014, Annals of neurology.

[44]  M. Mattson,et al.  Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo , 1998, Journal of neuroscience research.